Browsing by Yonsei Author : Kim, Hye Ryun

eperson profile image
Name:
Kim, Hye Ryun [김혜련]
orcid http://orcid.org/0000-0002-1842-9070
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (8583782700)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 178

This table browses all dspace content
Issue DateTitleJournal Title
2022Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation THERANOSTICS
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2022A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors JOURNAL OF THORACIC ONCOLOGY
2022Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice CLINICAL CANCER RESEARCH
2022Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice CURRENT ONCOLOGY
2022Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma CLINICAL AND TRANSLATIONAL MEDICINE
2022Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapyRADIOTHERAPY AND ONCOLOGY
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy IMMUNE NETWORK
2022The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2022Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01) CANCER RESEARCH AND TREATMENT
2022Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01) KOREAN JOURNAL OF INTERNAL MEDICINE
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2021SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2021Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck ESMO OPEN
2021Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort JOURNAL OF THORACIC ONCOLOGY
2021Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial JOURNAL OF THORACIC ONCOLOGY
2021Therapeutic Singing as a Swallowing Intervention in Head and Neck Cancer Patients With Dysphagia INTEGRATIVE CANCER THERAPIES
2021두경부암의 최신 표적치료Korean Journal of Head & Neck Oncology(대한두경부종양학회지)
2021Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma JOURNAL OF CLINICAL INVESTIGATION
2021Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer JOURNAL FOR IMMUNOTHERAPY OF CANCER
2021Role and Function of O-GlcNAcylation in Cancer CANCERS
2021Dysregulation of T FH-B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer NATURE COMMUNICATIONS
2021Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations INVESTIGATIONAL NEW DRUGS
2021Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer ANNALS OF ONCOLOGY
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Human reference gut microbiome catalog including newly assembled genomes from under-represented Asian metagenomesGENOME MEDICINE
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2021Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 CANCER RESEARCH AND TREATMENT
2021A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma CANCER MEDICINE
2021Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study CANCERS
2021Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy CANCERS
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2021Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer MOLECULES AND CELLS
2021Clinical Insights Into Novel Immune Checkpoint Inhibitors FRONTIERS IN PHARMACOLOGY
2021Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 JOURNAL OF CLINICAL ONCOLOGY
2021Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients SCIENTIFIC REPORTS
2021Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma SCIENTIFIC REPORTS
2021Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques FRONTIERS IN ONCOLOGY
2021A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancerBRITISH JOURNAL OF CANCER
2021Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinomaJOURNAL OF HEPATOLOGY
2021Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2020Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2020Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L TrialJOURNAL OF CLINICAL ONCOLOGY
2020The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma JOURNAL OF THORACIC DISEASE
2020Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 SignalingCANCER IMMUNOLOGY RESEARCH
2020Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinomaCANCER
2020Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancerEXPERIMENTAL AND MOLECULAR MEDICINE

Browse

Links